Search

Background: High-level resistance to sulfadoxine-pyrimethamine threatens the efficacy of WHO-recommended intermittent preventive treatment in pregnancy (IPTp) with single-dose sulfadoxine-pyrimethamine to prevent malaria. Monthly IPTp with dihydroartemisinin-piperaquine, a 3-day regimen, is an emerging alternative, but this regimen poses potential implementation and adherence challenges. We aimed to assess adherence to a multiday IPTp with dihydroartemisinin-piperaquine regimen and its delivery effectiveness in routine antenatal care settings in western Kenya., Methods: We conducted a pragmatic, three-armed, open-label, cluster-randomised trial in antenatal clinics in 18 health-care facilities (six facilities per group) in Kisumu County and Homa Bay County in western Kenya. Clusters were facilities offering routine antenatal care services provided by trained Ministry of Health staff with 100 or more antenatal clinic attendances per month between July, 2018, and June, 2019. Private or mission hospitals, dispensaries, referral hospitals, and trial sites were excluded. Individuals in their first trimester, living with HIV, or who were not attending a scheduled antenatal clinic visit were excluded. The 18 antenatal clinics were grouped into matched triplets stratified by location and clinics in each matched triplet were randomly assigned to one of the three study groups (1:1:1). Masking was not possible. Two groups were given IPTp with dihydroartemisinin-piperaquine (one group with a targeted information transfer intervention and one group without any additional interventions) and one group was given the standard of care (ie, IPTp with sulfadoxine-pyrimethamine). The primary endpoint, adherence, was defined as the proportion of participants completing their most recent 3-day IPTp with dihydroartemisinin-piperaquine regimen. This completion was verified by pill counts during home visits no more than 2 days after participants' 3-day regimens ended. The secondary endpoint, delivery effectiveness, was defined as the proportion of participants who received the correct number of IPTp tablets and correctly repeated dosing instructions (ie, correctly recalled the instructions they received about self-administered dihydroartemisinin-piperaquine doses and the number of sulfadoxine-pyrimethamine tablets they had received) at their exit from the antenatal clinic. Individuals receiving treatment for malaria, visiting a clinic for registration only, or interviewed during IPTp drug stock-outs were excluded from analyses. We used generalised linear mixed models to compare endpoints among the IPTp with dihydroartemisinin-piperaquine groups. This trial was registered with ClinicalTrials.gov, NCT04160026, and is complete., Findings: 15 facilities (five per group) completed the trial, with 1189 participants having exit interviews (377 in the IPTp with sulfadoxine-pyrimethamine group, 408 in the IPTp with dihydroartemisinin-piperaquine only group, and 404 in the IPTp with dihydroartemisinin-piperaquine plus targeted information transfer intervention group) and 586 participants having home visits (267 in the IPTp with dihydroartemisinin-piperaquine only group and 319 in the IPTp with dihydroartemisinin-piperaquine plus targeted information transfer intervention group) from Sept 8 to Dec 10, 2020. Relative to the IPTp with dihydroartemisinin-piperaquine only group, adherence was 16% higher in the IPTp with dihydroartemisinin-piperaquine plus targeted information transfer intervention group (266 [83%] of 319 participants vs 196 [73%] of 267 participants; adjusted relative risk [RR] 1·16, 95% CI 1·03-1·31; p=0·0140). Delivery effectiveness in the IPTp with dihydroartemisinin-piperaquine plus targeted information transfer intervention group was not significantly different from that in the IPTp with sulfadoxine-pyrimethamine group (352 [87%] of 403 participants vs 335 [89%] of 375 participants; adjusted RR 0·97, 95% CI 0·90-1·05; p=0·4810). However, delivery effectiveness in the IPTp with dihydroartemisinin-piperaquine only group was significantly lower than in the IPTp with sulfadoxine-pyrimethamine group (300 [74%] of 404 participants vs 335 [89%] of 375 participants; 0·84, 0·75-0·95; p=0·0030)., Interpretation: Targeted information transfer interventions to health-care providers and pregnant individuals boost antenatal care delivery adherence to a multiday regimen with dihydroartemisinin-piperaquine., Funding: European and Developing Countries Clinical Trials Partnership 2, UK Joint Global Health Trials Scheme of the Foreign, Commonwealth and Development Office, Medical Research Council, National Institute for Health and Care Research, and Wellcome Trust; and Swedish International Development Cooperation Agency., Competing Interests: Declaration of interests We declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)

Synthesis and catalytic studies of aryl carboxylate Zn (II) complexes is reported. Reaction of substituted ( E )- N -phenyl-1-(pyridin-4-yl)methanimine with a methanolic solution of Zn(CH 3 COO) 2 and substituted aryl carboxylate co-ligands gave heteroleptic Zn(II) complexes; [Zn(C 6 H 5 COO) 2 ( L1 )] 2 ( 1 ), [Zn(C 7 H 7 COO) 2 ( L1 )] 2 ( 2 ), [Zn (4-F-C 6 H 4 COO) 2 ( L1 )] 2 ( 3 ), [Zn(C 6 H 5 COO) 2 ( L2 )] 2 ( 4 ), [Zn(C 7 H 7 COO) 2 ( L2 )] 2 ( 5 ), [Zn (4-F-C 6 H 4 COO) 2 ( L2 )] 2 ( 6 ), [Zn(C 6 H 5 COO) 2 ( L3 )] 2 ( 7 ), [Zn(C 7 H 7 COO) 2 ( L3 )] 2 ( 8 ), [Zn (4-F-C 6 H 4 COO) 2 ( L3 )] 2 ( 9 ). The molecular structures of complexes 1 and 4 are dinuclear with the zinc atom in complex 1 adopting a distorted trigonal bipyramidal geometry in a bi-metallacycle while complex 4 is square pyramidal where all four benzoate ligands bridge the zinc metals in a paddle wheel arrangement. All complexes successfully initiated mass/bulk ring-opening polymerization (ROP) of ϵ-caprolactone (ϵ-CL) and lactides (LAs) monomers with or without alcohol co-initiators at elevated temperatures. Complexes 1 , 4 and 6 containing the unsubstituted benzoate co-ligands were the most active in their triad; with complex 4 being the most active ( k app ) of 0.3450 h -1 . The physicochemical properties of the polymerization products of l -lactide and rac -lactide in toluene revealed melting temperatures (T m ) between 116.58 °C and 188.03 °C, and decomposition temperatures between 278.78 °C and 331.32 °C suggestive of an isotactic PLA with a metal capped end., Competing Interests: The authors declare no competing interests., (© 2023 The Authors.)

Six ferrocenyl imidazole derivatives substituted with -Cl, -NO 2 and -CH 3 on the 2-position of the 1H-imidazole ring have been synthesized. Of the six compounds, the di-substituted ferrocenes, i.e. compounds 4 (1,1'-ferrocenylmethyl(2-chloroimidazole)), 5 (1,1'-ferrocenyl(2-nitroimidazole)), and 6 (1,1'-ferrocenylmethyl(2-methylimidazole)) are reported for the first time. The structure-property relationships of compounds 4 , 5 and 6 were investigated by means of UV-visible, FTIR, 1 H-NMR, 13 C-NMR spectroscopy and electrochemical studies. UV-visible analysis in acetonitrile showed that the π -π* band of compounds 2 (1-ferrocenylmethyl(2-nitroimidazole)) and 5 appeared at longer wavelength compared to 1 (1-ferrocenylmethyl(2-chloroimidazole)), 3 (1-ferrocenylmethyl(2-methylimidazole)), 4 and 6 . This phenomenon is due to the different electronics around the imidazole moieties. In cyclic voltammetry analysis, all compounds exhibited a quasi-reversible redox wave for the ferrocenyl and imidazole moieties. Density functional theoretical (DFT) calculations with the B3LYP/6-311+G(d) basis set were performed on compounds 1 - 6 , and the calculated HUMO-LUMO band gap energies correlated with those obtained from electrochemical and spectroscopic data. The X-ray crystallographic analysis highlighted the effect of electron-withdrawing and electron-donating substituents on the conformation of the cyclopentadienyl rings attached to the ferrocenyl moiety., (© 2019 The Author(s).)